Anders Erik Astrup Dahm
Overview
Explore the profile of Anders Erik Astrup Dahm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svalastoga M, Larsen T, Brekke J, Enden T, Froen H, Garresori H, et al.
Front Oncol
. 2025 Feb;
15:1520725.
PMID: 39931081
Introduction: It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients. Methods: A analysis of a single-arm interventional clinical trial on apixaban treatment...
2.
Storlien T, Dahm A
Tidsskr Nor Laegeforen
. 2023 Oct;
143(15).
PMID: 37874067
Background: It is uncertain what the best treatment is for older patients with acute myeloid leukaemia who are not candidates for allogeneic stem cell transplantation. The purpose of the study...
3.
Hussaini P, Larsen T, Ghanima W, Dahm A
Thromb Haemost
. 2023 Oct;
124(4):351-362.
PMID: 37816388
Background: Incidence of and risk factors for bleeding in cancer patients with venous thromboembolism (VTE) treated with apixaban are poorly described. Methods: We analyzed data from the prospective CAP study...
4.
Larsen T, Svalastoga M, Brekke J, Enden T, Froen H, Garresori H, et al.
Thromb Res
. 2023 Jun;
228:128-133.
PMID: 37327527
Introduction: In a recent interventional study of cancer patients with newly diagnosed venous thrombosis (VT), we found a high risk of arterial thrombotic events (AT) during treatment with therapeutic doses...
5.
Jervan O, Haukeland-Parker S, Gleditsch J, Tavoly M, Klok F, Steine K, et al.
Chest
. 2023 May;
164(4):981-991.
PMID: 37149257
Background: Persistent dyspnea, functional limitations, and reduced quality of life (QoL) are common following pulmonary embolism (PE). Rehabilitation is a potential treatment option, but the scientific evidence is limited. Research...
6.
Larsen T, Ghanima W, Sandset P, Froen H, Jacobsen E, Torfoss D, et al.
Tidsskr Nor Laegeforen
. 2023 Jan;
142(1).
PMID: 36655971
Venous thromboembolism is a common complication of cancer. The prevalence varies according to cancer type and increases proportionally with the stage of cancer. In the past 15-20 years, low molecular...
7.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost
. 2022 Jul;
20(8):1937-1939.
PMID: 35859282
No abstract available.
8.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost
. 2022 Feb;
20(5):1166-1181.
PMID: 35114046
Background: There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban...
9.
Dahm A
Med Sci (Basel)
. 2021 Jul;
9(2).
PMID: 34204957
The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in cancer patients. The clinicians are, however, faced with...
10.